Venetoclax As a Single Agent and in Combination with PI3K-MTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

Overview

Journal Br J Haematol

Specialty Hematology

Date 2018 Feb 1

PMID 29383700

Citations 8

Authors

Huijuan Jiang

Tint Lwin

Xiaohong Zhao

Yuan Ren

Grace Li

Lynn Moscinski

Bijal Shah

Jianguo Tao

Affiliations

Soon will be listed here.

Citing Articles

Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies.

Bettazova N, Senavova J, Kupcova K, Sovilj D, Rajmonova A, Andera L Blood Adv. 2024; 8(20):5279-5289.

PMID: 39158100 PMC: 11497468. DOI: 10.1182/bloodadvances.2024013205.

Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells.

Sneyers F, Kerkhofs M, Speelman-Rooms F, Welkenhuyzen K, La Rovere R, Shemy A Cell Death Dis. 2023; 14(9):600.

PMID: 37684238 PMC: 10491774. DOI: 10.1038/s41419-023-06120-4.

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.

Thus Y, de Rooij M, Swier N, Beijersbergen R, Guikema J, Kersten M Haematologica. 2022; 108(3):797-810.

PMID: 36226498 PMC: 9973496. DOI: 10.3324/haematol.2022.281668.

Programmed cell death, redox imbalance, and cancer therapeutics.

Dai X, Wang D, Zhang J Apoptosis. 2021; 26(7-8):385-414.

PMID: 34236569 DOI: 10.1007/s10495-021-01682-0.

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.

Zhao X, Wang M, Jiang H, Lwin T, Park P, Gao J Cell Rep. 2021; 34(11):108870.

PMID: 33730585 PMC: 8057695. DOI: 10.1016/j.celrep.2021.108870.

References

Campo E, Rule S . Mantle cell lymphoma: evolving management strategies. Blood. 2014; 125(1):48-55. DOI: 10.1182/blood-2014-05-521898. View

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

Davids M, Letai A . Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012; 30(25):3127-35. PMC: 4979238. DOI: 10.1200/JCO.2011.37.0981. View

Vogler M, Dinsdale D, Dyer M, Cohen G . ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013; 163(1):139-42. DOI: 10.1111/bjh.12457. View

Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson J, Souers A . The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2013; 28(1):210-2. PMC: 3887407. DOI: 10.1038/leu.2013.216. View